Assessing the Utility of Submaximal CPET in Treatment Management of PAH

Status unconfirmed

Conditions studied: Pulmonary Arterial Hypertension

In brief

Pulmonary hypertension (PH) is associated with worsening breathlessness and exercise capacity, right-heart failure, and adverse outcomes including increased mortality. Moreover, PH disease progression can be rapid; pharmaceutical intervention in early-stage Pulmonary Hypertension (PH) can improve symptoms and functional capacity, and delayed diagnosis and treatment of Pulmonary Hypertension (PH) likely reduces survival.

Key facts

Study ID

NCT05977933

Run by

Shape Medical Systems, Inc.

People needed

550

Starts

2024-04-01

Expected to finish

2024-12-30

Last updated by the study team

2024-03-13

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Harbor-UCLA Medical Center — Torrance, California, United States
• National Jewish Health — Denver, Colorado, United States
• Mayo Clinic — Jacksonville, Florida, United States
• WellStar Health System — Atlanta, Georgia, United States
• Southeastern Cardiology — Columbus, Georgia, United States
• Weill Cornell Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.